Nektar Therapeutics (NKTR) News
Follow Nektar Therapeutics (NKTR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 25 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Nektar Therapeutics to Report Q3 2026 Results Nov. 12 After Close
Nektar Therapeutics will release its Q3 2026 financial results on Nov. 12 after the U.S. market close, followed by a conference call at 5:00 p.m. ET.
EQUITY | Oct 27, 2026, 10:01 PM UTC
M
NKTR Stock Plunges on Rezpegaldesleukin Data; William Blair Maintains Durability View
Nektar Therapeutics (NKTR) shares dropped 21% on Thursday after the company presented new response rate data for its experimental skin drug, rezpegaldesleukin. While the drug reportedly maintained efficacy after treatmen
EQUITY | Oct 01, 2026, 07:42 PM UTC
L
Weekly Recap: Phase 3 ZENITH AD trials and $90M jury award
Nektar Therapeutics (NASDAQ:NKTR) is advancing rezpegaldesleukin with two global Phase 3 ZENITH AD trials (a third planned) even as Wedbush flags safety/efficacy concerns and a $50 target, the company won a $90M jury awa
NEWS | Sep 28, 2026, 11:04 AM UTC
L
Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 10:11 AM UTC
L
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 212.0% from the Sep 25 close of $57.06.Key takeaways from the analyst noteStrong Clinic
EQUITY | Sep 28, 2026, 10:01 AM UTC
L
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 25, 2026 // -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock op
EQUITY | Sep 25, 2026, 08:15 PM UTC
H
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says
By Blake BrittainA federal jury in California has determined that Eli Lilly NYSE:LLY must pay Nektar Therapeutics NASDAQ:NKTR $90 million for breaking an agreement related to an autoimmune drug candidate that the compani
NEWS | Sep 25, 2026, 03:14 PM UTC
L
Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 02:42 PM UTC
L
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 199.8% from the Sep 24 close of $59.38.Key takeaways from the analyst noteStrong Safety
EQUITY | Sep 25, 2026, 02:32 PM UTC
L
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update
By Colin KellaherNektar Therapeutics said it has won a $90 million verdict in its lawsuit against Eli Lilly related to the development of its proposed autoimmune drug rezpegaldesleukin, or rezpeg.Nektar on Friday said a
REGULATION | Sep 25, 2026, 01:37 PM UTC
L
Nektar Gets $90 Million Jury Award in Breach Suit Vs Eli Lilly
By Colin KellaherNektar Therapeutics said it has won a $90 million verdict in its lawsuit against Eli Lilly related to the development of its proposed autoimmune drug Rezpegaldesleukin, or rezpeg.Nektar said a California
REGULATION | Sep 25, 2026, 12:09 PM UTC
L
Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute
Nektar Therapeutics won a $90 million jury verdict finding Eli Lilly breached the implied covenant under their rezpegaldesleukin license agreement.Key Highlights:Original SEC Filing: NEKTAR THERAPEUTICS [ NKTR ] - 8-K -
REGULATION | Sep 25, 2026, 11:04 AM UTC
L
Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement
Eli Lilly and Company NYSE:LLY
NEWS | Sep 25, 2026, 11:03 AM UTC
L
Nektar Therapeutics Is Maintained at Neutral by Wedbush
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:29 PM UTC
L
Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target
Wedbush maintained their Neutral rating on Nektar Therapeutics's stock with a price target of $50.00.The price target implies a downside of 18.0% from the Sep 22 close of $60.97.Key takeaways from the analyst noteConcern
EQUITY | Sep 23, 2026, 12:19 PM UTC
L
Nektar Therapeutics price target maintained at $178 by BTIG
BTIG maintained a $178.00/share price target for Nektar Therapeutics.
EQUITY | Sep 09, 2026, 10:29 AM UTC
L
Nektar enters quiet period ahead of REZOLVE-AA follow-up data
Nektar said its quiet period began Sept. 8, 2026, ahead of 24-week off-treatment follow-up data from the Phase 2b REZOLVE-AA study of rezpegaldesleukin.
REGULATION | Sep 08, 2026, 08:13 PM UTC
L
Nektar Therapeutics reports inducement grants under Nasdaq Rule 5635(c)(4)
Nektar Therapeutics (NKTR) reports inducement grants under Nasdaq listing rule 5635(c)(4).
EQUITY | Aug 28, 2026, 08:18 PM UTC
L
Nektar (NKTR) publishes positive Phase 2b REZOLVE-AD 16-week results in The Lancet
Nektar announces publication in The Lancet of positive Phase 2b REZOLVE-AD 16-week induction results for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
EQUITY | Aug 25, 2026, 12:30 PM UTC
L
JPMorgan initiates NKTR at Neutral with $65 price target
JPMorgan initiates coverage of NKTR with a Neutral rating and a $65.00 price target.
EQUITY | Aug 21, 2026, 11:58 AM UTC
L
Nektar Therapeutics reports Second Quarter 2026 financial results
Nektar Therapeutics (NKTR) announces its Second Quarter 2026 financial results, but the feed provides no further figures or guidance details.
EARNINGS | Aug 13, 2026, 08:15 PM UTC
L
NKTR NKTR - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
NKTR NKTR - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
EARNINGS | Jul 28, 2026, 10:00 PM UTC
L
NKTR Maintain Buy and $151 PT after Ph3 Initiation in Ad Marks Key Milestone for Rezpeg @ Citi
NKTR Maintain Buy and $151 PT after Ph3 Initiation in Ad Marks Key Milestone for Rezpeg @ Citi
EQUITY | Jul 22, 2026, 01:08 PM UTC
L
NKTR Initiated Buy W/$153.00 PT at Canaccord
NKTR Initiated Buy W/$153.00 PT at Canaccord
EQUITY | Jul 22, 2026, 12:02 PM UTC
L
NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moder
NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics - initial phase 3 topline da
EQUITY | Jul 21, 2026, 11:04 AM UTC